In the current study, the genotypes at polymorphic locations -656 (G/T), -607 (C/A), and -137 (G/C) of the IL-18 promoter region among RCC patients and healthy individuals in a Taiwan population were first determined and evaluated for their contribution to RCC risk. This evidence concerns the gene IL18 and renal cell carcinoma.